Our Sponsors

Gold Sponsors


Powering the heroes on the front lines with sequencing solutions to address a pandemic In these unprecedented times, there are no borders, countries, mine, or yours. There’s only one focus: how do we stop COVID-19.As the world’s leader in next-generation sequencing, our technology helps power the heroes working around the clock to track transmission, conduct surveillance, develop therapies and vaccines, and protect our neighbors around the globe for years to come.	BioMarin is a world leader in developing and commercializing innovative biopharmaceuticals for rare genetic diseases.BioMarin focuses on developing first-in-class or best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. BioMarin remains steadfast in its original mission — to bring new treatments to market that will make a big impact on small patient populations. These patient populations suffer from diseases so rare that they can affect as few as 1,000 people worldwide. The conditions are often inherited, difficult to diagnose, progressively debilitating and have few, if any, treatment options.As a multinational biopharmaceutical company, BioMarin’s success stems from its focus on science and the hope its therapies may bring to patients. BioMarin is a world leader in metabolic disease innovation with multiple commercialised products and a growing pipeline of product candidates to address unmet medical needs. BioMarin continually looks for opportunities that align with the strengths and competencies of the company to relentlessly pursue exciting, early-stage science that may have the potential to change the course of disease.A constant in BioMarin’s culture is how patients continue to be a key driver. The passion and dedication that BioMarin’s employees demonstrate at work each day is a testament to the inspiration provided by patients, and the knowledge of the impact that may be made on their lives.

Silver Sponsors

Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases. We are committed to helping change the lives of patients and their families. With one rare disease medicine globally commercialized for Fabry disease, an investigational enzyme replacement therapy (AT-GAA) in late stage development for the treatment of Pompe disease, and a robust gene therapy pipeline and growth platform for lysosomal storage disorders, Amicus Therapeutics is committed to changing the lives of people with these life-threatening conditions. We believe every step towards bettering patients’ lives is a step in the right direction patients and their families

At Novartis, our purpose is to reimagine medicine to improve and extend people’s lives. We use innovative science and technology to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. Our strategy is to build a leading, focused medicines company powered by advanced therapy platforms and data science. Novartis Gene Therapies is reimagining medicine with one-time, potentially curative gene therapies that only need to be administered once for patients with serious, rare and life-threatening needs.

Virtual Exhibition Sponsors

Our Sponsors

Gold Sponsors

Silver Sponsors

Virtual Exhibition Sponsors

Contact